Volume 27, Number 11—November 2021
Dispatch
Bordetella hinzii Pneumonia and Bacteremia in a Patient with SARS-CoV-2 Infection
Table 2
Characteristics of previously reported Bordetella hinzii infections*
Ref.† | Type of infection | Age, y | Underlying conditions | Animal exposure | Antimicrobial drugs | Patient outcome |
---|---|---|---|---|---|---|
(5) |
Bacteremia |
24 |
HIV/AIDS |
None |
Ceftazidime |
Recovered |
(4) |
Pneumonia |
NA |
HIV/AIDS |
None |
NA |
NA |
(6) |
Bacteremia and cholangitis |
69 |
None |
None |
Ticarcillin/sulbactam, ciprofloxacin |
Died |
(7) |
Cholangitis |
29 |
Primary sclerosing cholangitis, liver transplant recipient |
None |
Meropenem |
Died |
(8) |
Bacteremia |
79 |
Myelodysplastic syndrome |
None |
Ceftazidime |
Recovered |
(9) |
Bacteremia |
36 |
EBV associated diffuse large cell lymphoma |
None |
Meropenem |
Died |
(10) |
Pneumonia |
43 |
AML, transplant, diabetes bronchiectasis |
Poultry |
Piperacillin/tazobactam, ciprofloxacin |
Recovered |
(10) |
Pneumonia |
74 |
Laryngeal cancer, prostate cancer, diabetes, COPD |
None |
Piperacillin/tazobactam |
Recovered |
(11) |
Urinary tract infection |
55 |
None |
Possible poultry |
Trimethoprim/
sulfamethoxazole |
Recovered |
(11) |
Liver abscess |
58 |
Hypothyroidism, cholecystectomy |
None |
None |
Recovered |
(12) |
Bacteremia and infective endocarditis |
79 |
Aortic valve replacement, diabetes, cirrhosis, colon cancer, kidney disease |
None |
Meropenem |
Recovered |
(13) |
Bacteremia and infective endocarditis |
53 |
Ulcerative colitis |
None |
Ceftazidime |
Recovered |
(14) |
Soft tissue abscess |
63 |
None |
None |
Sitafloxacin |
Recovered |
(15) |
Pancreatic abscess |
42 |
Alcoholic liver disease |
None |
Tigecycline |
Recovered |
(16) |
Urinary tract infection |
37 |
Chronic alcohol use |
None |
Trimethoprim/sulfamethoxazole |
Recovered |
(17) | Pneumonia | 67 | Diabetes mellitus | None | Cefmetazole | Recovered |
*AML, Acute myeloid leukemia; COPD, chronic obstructive pulmonary disease; EBV, Epstein-Barr virus; NA, not available; ref., reference. †References 16,17 in Appendix.
References
- Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol. 2020;104:7777–85. DOIPubMedGoogle Scholar
- Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005;18:326–82. DOIPubMedGoogle Scholar
Page created: August 05, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.